Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers
- PMID: 17078017
- DOI: 10.1002/pmic.200600135
Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers
Abstract
CNS diseases are often accompanied by changes in the protein composition of cerebrospinal fluid (CSF). SELDI-TOF-MS provides an approach for identifying specific protein markers of disease in biological fluids. We compared the CSF proteomes from patients with neoplastic and reactive/inflammatory CNS diseases to identify potential biomarkers. SELDI-TOF-MS was performed on CSF derived from lumbar puncture of 32 patients, including 10 with CNS malignancies, 12 with inflammatory or reactive conditions, and 10 with unknown CNS disease. Using the SAX-2 (strong anionic exchange) chip, we uncovered three conserved protein peak ranges within each disease category. For neoplastic diseases, we identified conserved peaks at 7.5-8.0 kDa (9/10 samples), 15.1-15.9 kDa (8/10 samples), and 30.0-32.0 kDa (5/10 samples). In reactive/inflammatory diseases, conserved peaks were found at 6.7-7.1 kDa (10/12 samples), 11.5-11.9 kDa (12/12 samples), and 13.3-13.7 kDa (9/12 samples). A protein from the 30.0 to 32.0 kDa peak range found in neoplastic CSF was identified by MALDI analysis as carbonic anhydrase, a protein overexpressed in many malignancies including high-grade gliomas. Similarly, cystatin C was identified in the 13.3-13.7 kDa peak range in non-neoplastic CSF and was most prominent in inflammatory conditions. Our approach provides a rational basis for identifying biomarkers that could be used for detection, diagnosis, and monitoring of CNS diseases.
Similar articles
-
Identification of potential CSF biomarkers in ALS.Neurology. 2006 Apr 25;66(8):1218-22. doi: 10.1212/01.wnl.0000203129.82104.07. Epub 2006 Feb 15. Neurology. 2006. PMID: 16481598
-
Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.Ann Neurol. 2012 May;71(5):614-23. doi: 10.1002/ana.22633. Ann Neurol. 2012. PMID: 22522477
-
Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform.J Proteome Res. 2008 Feb;7(2):720-30. doi: 10.1021/pr700630x. Epub 2008 Jan 11. J Proteome Res. 2008. PMID: 18186601
-
Identification of glycoproteins in human cerebrospinal fluid.Methods Mol Biol. 2009;566:263-76. doi: 10.1007/978-1-59745-562-6_17. Methods Mol Biol. 2009. PMID: 20058177 Review.
-
Proteomics analysis of human cerebrospinal fluid.J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 5;815(1-2):179-89. doi: 10.1016/j.jchromb.2004.06.044. J Chromatogr B Analyt Technol Biomed Life Sci. 2005. PMID: 15652808 Review.
Cited by
-
Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients.Mol Vis. 2009 Aug 19;15:1638-48. Mol Vis. 2009. PMID: 19710940 Free PMC article.
-
Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study.Proteomics. 2011 Mar;11(5):935-43. doi: 10.1002/pmic.201000198. Epub 2011 Jan 27. Proteomics. 2011. PMID: 21271676 Free PMC article.
-
Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors.J Neurooncol. 2014 Jun;118(2):225-238. doi: 10.1007/s11060-014-1432-3. Epub 2014 Apr 26. J Neurooncol. 2014. PMID: 24771250 Review.
-
Diagnosis of malignant glioma: role of neuropathology.J Neurooncol. 2008 Sep;89(3):287-311. doi: 10.1007/s11060-008-9618-1. Epub 2008 Aug 20. J Neurooncol. 2008. PMID: 18712282 No abstract available.
-
Proteomics of gliomas: initial biomarker discovery and evolution of technology.Neuro Oncol. 2011 Sep;13(9):926-42. doi: 10.1093/neuonc/nor078. Neuro Oncol. 2011. PMID: 21852429 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical